Pomalidomide plus low‐dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pomalidomide plus low‐dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure
Authors
Keywords
-
Journal
BRITISH JOURNAL OF HAEMATOLOGY
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2019-10-07
DOI
10.1111/bjh.16213
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide
- (2019) Philippe Moreau et al. Blood Cancer Journal
- Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
- (2019) Paul G Richardson et al. LANCET ONCOLOGY
- Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study design
- (2018) Paul G Richardson et al. Future Oncology
- Immunopathogenesis and immunotherapy of multiple myeloma
- (2018) Hideto Tamura INTERNATIONAL JOURNAL OF HEMATOLOGY
- Drug resistance in multiple myeloma
- (2018) Pawel Robak et al. CANCER TREATMENT REVIEWS
- Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma
- (2018) Meletios A. Dimopoulos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Triplet vs. doublet drug regimens for managing multiple myeloma
- (2017) Massimo Offidani et al. EXPERT OPINION ON PHARMACOTHERAPY
- Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study
- (2017) S K Kumar et al. LEUKEMIA
- Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma
- (2016) M. A. Dimopoulos et al. BLOOD
- Pomalidomide in combination with dexamethasone results in synergistic anti-tumour responses in pre-clinical models of lenalidomide-resistant multiple myeloma
- (2016) Emily Rychak et al. BRITISH JOURNAL OF HAEMATOLOGY
- Multiple myeloma: patient outcomes in real-world practice
- (2016) Kwee Yong et al. BRITISH JOURNAL OF HAEMATOLOGY
- Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies
- (2016) Camille Guillerey et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Immune Therapies in Multiple Myeloma
- (2016) Shaji K. Kumar et al. CLINICAL CANCER RESEARCH
- Treatment of relapsed and refractory multiple myeloma
- (2016) Pieter Sonneveld et al. HAEMATOLOGICA
- Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
- (2016) Philippe Moreau et al. NEW ENGLAND JOURNAL OF MEDICINE
- Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
- (2016) Meletios A. Dimopoulos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Occurrence and prognostic significance of cytogenetic evolution in patients with multiple myeloma
- (2016) M Binder et al. Blood Cancer Journal
- Treatment of relapsed and refractory multiple myeloma
- (2016) Pieter Sonneveld et al. HAEMATOLOGICA
- Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma
- (2015) J. J. Shah et al. BLOOD
- Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets
- (2015) K. Sehgal et al. BLOOD
- Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
- (2015) Sagar Lonial et al. NEW ENGLAND JOURNAL OF MEDICINE
- Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
- (2015) A. Keith Stewart et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rate of CRL4CRBN substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4
- (2015) C C Bjorklund et al. Blood Cancer Journal
- Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study
- (2014) P. G. Richardson et al. BLOOD
- Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy
- (2014) Jens G. Lohr et al. CANCER CELL
- In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone
- (2014) E M Ocio et al. LEUKEMIA
- Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myelome 2009-02
- (2013) X. Leleu et al. BLOOD
- Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial
- (2013) Jesus San Miguel et al. LANCET ONCOLOGY
- Multiple myeloma is affected by multiple and heterogeneous somatic mutations in adhesion- and receptor tyrosine kinase signaling molecules
- (2013) E Leich et al. Blood Cancer Journal
- Clonal competition with alternating dominance in multiple myeloma
- (2012) J. J. Keats et al. BLOOD
- Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide
- (2012) A Lopez-Girona et al. LEUKEMIA
- Minor clone provides a reservoir for relapse in multiple myeloma
- (2012) F Magrangeas et al. LEUKEMIA
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started